Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: Implications for cellular Aβ metabolism  by Leal, María C. et al.
Biochimica et Biophysica Acta 1823 (2012) 227–235
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrNotch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE)
proximal promoter and repress its transcription and activity: Implications for cellular
Aβ metabolism
María C. Leal a,1, Ezequiel I. Surace a,1, María P. Holgado a, Carina C. Ferrari a, Rodolfo Tarelli a,
Fernando Pitossi a, Thomas Wisniewski b, Eduardo M. Castaño a, Laura Morelli a,⁎
a Fundación Instituto Leloir - Instituto de Investigaciones Bioquímicas Buenos Aires - Consejo Nacional de Investigaciones Cientíﬁcas y Técnicas (CONICET), Patricias Argentinas 435,
C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina
b New York University School of Medicine, Dept. of Neurology, Psychiatry and Pathology, 550 First Ave. New York, NY 10016, USA⁎ Corresponding author at: Patricias Argentinas 435.
de Buenos Aires, Argentina. Tel.: +54 11 5238 7500; fa
E-mail address: lmorelli@leloir.org.ar (L. Morelli).
1 Contributed equally to this work.
0167-4889/$ – see front matter © 2011 Elsevier B.V. All
doi:10.1016/j.bbamcr.2011.09.014a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 July 2011
Received in revised form 9 September 2011
Accepted 12 September 2011
Available online 19 October 2011
Keywords:
Amyloid β metabolism
Notch signaling
HES
Hey
Transcriptional repressors
IDE gene promoterCerebral amyloid β (Aβ) accumulation is pathogenically associated with sporadic Alzheimer's disease (SAD).
BACE-1 is involved in Aβ generation while insulin-degrading enzyme (IDE) partakes in Aβ proteolytic clear-
ance. Vulnerable regions in AD brains show increased BACE-1 protein levels and enzymatic activity while the
opposite occurs with IDE. Another common feature in SAD brains is Notch1 overexpression. Here we demon-
strate an increase in mRNA levels of Hey-1, a Notch target gene, and a decrease of IDE transcripts in the hip-
pocampus of SAD brains as compared to controls. Transient transfection of Notch intracellular domain (NICD)
in N2aSW cells, mouse neuroblastoma cells (N2a) stably expressing human amyloid precursor protein (APP)
Swedish mutation, reduce IDEmRNA levels, promoting extracellular Aβ accumulation. Also, NICD, HES-1 and
Hey-1 overexpression result in decreased IDE proximal promoter activity. This effect was mediated by 2 func-
tional sites located at −379/−372 and −310−303 from the ﬁrst translation start site in the −575/−19
(556 bp) fragment of IDE proximal promoter. By site-directed mutagenesis of the IDE promoter region we
reverted the inhibitory effect mediated by NICD transfection suggesting that these sites are indeed responsi-
ble for the Notch-mediated inhibition of the IDE gene expression. Intracranial injection of the Notch ligand
JAG-1 in Tg2576 mice, expressing the Swedish mutation in human APP, induced overexpression of HES-1
and Hey-1 and reduction of IDE mRNA levels, respectively. Our results support our theory that a Notch-
dependent IDE transcriptional modulation may impact on Aβ metabolism providing a functional link be-
tween Notch signaling and the amyloidogenic pathway in SAD.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
In the rare familial Alzheimer's disease (FAD) cases, mutations in
the amyloid precursor protein (APP) or presenilin genes result in in-
creased amyloid β (Aβ) concentration in the brain [1]. Yet, the mech-
anisms of Aβ accumulation in sporadic AD (SAD) remain largely
unknown. Notably, Down Syndrome (DS) patients, who harbor a
chromosome 21 trisomy, almost invariably exhibit Aβ accumulation
in senile plaques at adulthood. The fact that these patients carry an
extra APP gene copy may be a plausible explanation for the observed
AD-like brain pathology [2]. However, recent work has shown that
APPwas not over-expressed in a cohort of adult DS brains as assessed
by microarray QPCR [3] whereas, as expected, a subset ofC1405BWE Ciudad Autónoma
x: +54 11 5238 7501.
rights reserved.chromosome 21 genes was found to be up-regulated. The lack of
APP over-expression suggests that post-translational disturbances in
APP processing, trafﬁcking or Aβ metabolism may be more relevant
than the levels of APP to amyloid deposition in DS brain. In addition,
the brain of adult DS patients showed up-regulation of several genes
involved in developmental processes including components of the
Notch signaling pathway. This observation was in agreement with
previous works indicating an increased Notch1 immunoreactivity in
the cerebellum and in the hippocampal formation of SAD brain as
compared to age-matched controls with a strong signal in neurons
of CA4, CA3 and CA2 ﬁelds and a weaker staining in the dentate
gyrus. In that report, neither neuroﬁbrillary tangles, senile plaques,
astrocytes nor microglial cells were positive for Notch1 labeling [4].
Taken together, these evidences raise the possibility that Notch acti-
vation is a common feature of AD and DS with pathogenic
implications.
Notch1 is a single-pass type I transmembrane receptor that is crit-
ical during development through the spatial and temporal regulation
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tissues and organs [5]. In adult brain, Notch signaling pathway has
been involved in neurogenesis, regulation of neurite growth, neuro-
nal plasticity and long-term memory [5–7]. Activation of the mam-
malian Notch pathway occurs when a speciﬁc ligand Delta/Jagged
binds to Notch extracellular domain. Sequential proteolytic events re-
sult in a γ-secretase-mediated release of a Notch intracellular domain
(NICD). Then, NICD translocates to the cell nucleus and elicits expres-
sion of two independent primary target genes, HES and Hey, which
are members of the bHLH family of transcriptional repressors [8].
Each works either individually or cooperatively to repress target
gene expression through its speciﬁc DNA-binding sites [9].
Aβ peptides are generated and released after a sequential proteo-
lytic processing of APP by β- and γ-secretases [10]. The ﬁrst cleavage
is mediated by β-secretase (BACE-1), the rate-limiting step in Aβ gen-
eration. Interestingly, BACE-1 protein levels and enzymatic activity
are increased in AD brains as compared to age-matched controls
[11], suggesting that BACE-1 may participate in AD pathogenesis by
accelerating the rate of Aβ production. In addition, Aβ concentration
in the brain is dependent upon its bi-directional transport across
the blood–brain barrier and its proteolytic degradation in situ.
The major peptidases that participate in the degradation of Aβ in-
clude the M13 zinc metallopeptidases, neprilysin (NEP) and its ho-
mologue endothelin-converting enzyme (ECE-1) and the M16
family member, insulin-degrading enzyme (IDE). Observations in
human postmortem tissue suggest that hippocampal NEP, ECE-1
and IDE expression and/or activity are inversely related to the extent
of AD pathology [12–17]. In addition, studies that focused on IDE in
the cortex rather than hippocampus, showed different results in
aging and AD [18] [19]. However, the mechanisms underlying the
transcriptional inhibition of Aβ-degrading proteases in SAD hippo-
campus remain mostly unknown. To address this issue we have
assessed the role of Notch signaling on the endogenous transcript
levels of IDE, the most relevant extracellular protease involved in
Aβ removal, which harbor putative HES/Hey-1 binding sites in its
promoter region.
In the present study, we demonstrate by several approaches that,
indeed, Notch signaling participates in the transcriptional regulation
of IDE in vitro and in vivo with impact on Aβ metabolism providing
a novel functional link between Notch activation and the amyloido-
genic pathway in SAD.
2. Materials and methods
2.1. In silico promoter analysis
Genomic sequence of the 4799 bp corresponding to the promoter
of the human IDE gene [20] (–4799/–18) up stream of the ﬁrst ATG)
was obtained from the GenBank database (accession number: NG
013012). Three different programs were run to detect putative
Notch target genes consensus binding sites as follows: TESS (Tran-
scription Element Search System), TF search software (www.cbrc.jp/
research/db/TFSEARCH.html) and Regulatory Sequence Analysis ToolTable 1
Summary of biological properties of the putative consensus binding sites of Notch target ge
Classiﬁcation Position* Orientation
N-box −3711/–3715
–310/–305
Foward (+)
Reverse (−)
Class C −379/–374 Reverse (−)
E-box −467/–462
−431/–425
Forward (+)
Foward/reverse (+)/(−)
Class B −308/–303 Foward (+)
*, From the ﬁrst translation start site (ATG). Class C and N-box are mutually overlapping. Clas
++, strong binding; +, weak binding.(RSAT) software (http://embnet.ccg.unam-mx/rsa-tools/). See
Table 1 for classiﬁcation, consensus and position of each site in
human IDE promoter.
2.2. Reagents
The γ-secretase inhibitor (GSI) IX (L-685,458) was purchased
from Calbiochem (Darmstadt, Germany). The 17-mer JAG-1 peptide
(CDDYYYGFGCNKFCRPR) was synthesized by Anaspec (Fremont,
USA). Peptide was dissolved in DMSO (for cell culture experiments)
or PBS (for in vivo experiments) at 50 mM, aliquoted, and stored at
−20 °C.
2.3. Antibodies
BC2 rabbit polyclonal and 1C1 and 3A2 monoclonal antibodies
anti-IDE were generated in our laboratory [21]. Rabbit anti-NICD
was purchased from Cell Signaling (Danvers, USA). This antibody tar-
gets the cleaved Val1754 of the Notch molecule. Polyclonal antibodies
anti-heterochromatin protein-1 (HP-1) and tubulin were from Sigma
(St. Louis, USA). Anti-HA antibody was purchased from Invitrogen
(Carlsbad, USA).
2.4. Human tissues
Frozen samples of hippocampus from late-onset SAD Braak stage
V (n=5) and age-matched controls (NDC, n=5) were kindly provid-
ed by the Harvard Brain Tissue Resource Center (Boston, USA). See
Table 2 for clinico-pathological features of each group. Frozen tissues
were homogenized as previously described [22] and nuclear fractions
conﬁrmed by immunoblotting for HP1.
2.5. cDNA constructs
HA-tagged Notch Intracellular Domain (NICD) cDNA was kindly
provided by Dr. Bettina Kempkes (German Research Center for Envi-
ronmental Health, Munich, Germany). A myc-tagged mouse Notch
construct lacking the extracellular domain (ΔE-Notch) was kindly
provided by Dr. Raphael Kopan (Washington University in St. Louis,
USA) [23]. HA-tagged Hey-1 construct was a kind gift from Dr.
Manfred Gessler (University of Wuerzburg Würzburg, Germany)
and the FLAG-tagged HES-1 construct was kindly provided by Dr. Sta-
fano Stifani (McGill University, Montreal, Canada). The region of
4799 bp 5′ upstream of human IDE gene (−4825/−26) cloned into
the pGL3-Basic vector (Promega, Madison, USA) was kindly provided
by Dr. Wesley Farris (Pittsburgh University, Pennsylvania, USA).
2.6. RNA extraction and quantitative real-time polymerase chain reac-
tion (QRT-PCR)
Total RNA was extracted from cells using RNAspin Mini kit (GE
Bioscience, Piscataway, USA) and from tissues using RNeasy Lipid Tis-
sue Mini Kit (Qiagen, Hilden, Germany). SuperScript II Reversenes in human IDE promoter.
Consensus bHLH protein DNA binding activity•
5′-CACNAG-3′ HES-1
Hey-1
++
+
5′-CACGNG-3′ Hey-1 ++
5′-CANNTG-3′ HES-2 ++
5′-CANGTG-3′ HES-1
Hey-1
+
++
s B is a subtype of E-box. •, The data are based on gel mobility shift assay as reported [9].
Table 2
Summary of clinico-pathological features of the autopsied cases of demented and con-
trol groups.
Group Number
of cases
Sex
(M:F)
PMD
(hours)
AAD•
(years)
SAD (Braak V) 5 2:3 22.80±1.44 78.2±6.13
NDC 5 5:0 25.29±1.15 67.0±3.0
AAD, Age at death; •, no statistical differences were detected between SAD and NDC; F,
female; M, male; PMD, post mortem delay; SAD, sporadic Alzheimer's disease; NDC,
non-demented control
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strand cDNA according to the manufacturer's instructions. Synthe-
sized cDNA was used in independent PCR reactions containing
6 mM MgCl2, 0.4 mM dNTP mixture, 200 nM each primer, 1 U Plati-
num Taq Polymerase (Invitrogen. Carlsbad, USA) SybrGreen and
ROX reference dye in appropriate buffer conditions. Reactions were
run in an Mx3005P Cycler (Stratagene, Santa Clara, USA). Data
were analyzed using MxPRO-Mx3005P software. Primers used
for IDE ampliﬁcation were: F: 5′-AAAGAAACTCTCTGCAGA-3′ and R:
5′-TTATGAATCACCTCAGGT-3′; for Hey-1 ampliﬁcation: Forward: 5′-
TGAGCTGAGAAGGCTGGTAC-3′ and R: 5′-ACCCCAAACTCCGA-
TAGTCC-3′; for BACE-1 ampliﬁcation: F: 5′-GATGGTGGACAACCT-
GAG-3′ and R: 5′-CTGGTAGTAGCGATGCAG-3′. Primers used
for TATA-Binding-Protein (TBP) ampliﬁcation were: F: 5′-
ACCGTGAATCTTGGCTGTAA -3′ and R: 5′-CCGTGGCTCTCTTATTCTCA
-3′ and for HPRT were: F: 5′-TGGGAGGCCATCACATTGTAG -3′ and R:
5′-TGTCCCCTGTTGACTGGTCATT -3′. TBP and HPRT were used as nor-
malizing genes.
2.7. Cell cultures, transient transfection and treatments
N2aSW (N2a mouse neuroblastoma cells stably expressing human
APP Swedish mutation [24] kindly provided by Dr. Gopal Tinakaran
from University of Chicago, USA) were maintained as previously de-
scribed [25]. Cells were plated at 70–80% conﬂuency 16 h prior to
transient transfection using Lipofectamine LTX (Invitrogen, Carlsbad,
USA) according to the manufacturer's instructions. Cells were har-
vested 24 h after transfection. The γ-secretase inhibitor was used at
a ﬁnal concentration of 20 μM. Cells were incubated with 100 μM
JAG-1 peptide for 48 h as previously reported [26].
2.8. SDS-PAGE and Western blots
Aliquots of 50 μg of nuclear fractions, 100 μg of cytosolic fractions
or 50 μg of cell homogenates were subjected to electrophoresis on
7.5% SDS-Tris-Tricine polyacrylamide mini-gels, and transferred to
polyvinylidene ﬂuoride (PVDF)-membranes (GE Bioscience, Piscat-
away, USA). Immunoreactivity was detected with HRP-coupled anti-
mouse or anti-rabbit IgG and ECL Plus (GE Bioscience, Piscataway,
USA). Immunoblots were scanned with STORM 840 and analyzed
with ImageQuant 5.1 software (GE Bioscience, Piscataway, USA).
2.9. Luciferase reporter assay
The fragment of 556 bp (–576/–19) upstream of the ﬁrst transla-
tional start site was ampliﬁed by PCR using as template the 5′ up-
stream region of human IDE gene and the following forward (F)
and reverse (R) primers: F-5′- GTATGGTACCCACGCCGCACTCGA- 3′
and R- 5′- GACTAAGCTTGATCACCGCAAACGCT-3′. For directional
cloning the restriction enzyme recognition sites KpnI and HindIII
were introduced in the F and R primers, respectively. PCR products
were cloned into the pGL3-basic (Promega, Madison, USA).The cor-
rect sequence and direction was conﬁrmed by sequencing (Macro-
gen, Seoul, Korea). To generate mutant versions of the 556 bp
construct site-directed mutagenesis was performed for the −431/−425 E-box, the −379/−372 Class C1 and the −310/−303 N-
box/Class B sites, respectively, using the following set of primers:
E-box (Mut1): 5′-CACGAACCTTGTTCCAATGCCTACAGGGTCCGG-
CACGCT-3′; Class C1 box (Mut2) 5′-GCCTCAGAAAACATAGCTCCG-
CATGCCCTCACTGGATTTA-3′ and N-box/Class B (Mut3): 5′-
ACACGTCGCCACCCTCATGAGTACGGCCGGTGGGATCTA-3′ and their
corresponding complementary primers. These primers were used in
separate temperature-cycling reactions using the 556 bp of IDE pro-
moter construct as template and Pfx DNA polymerase (Invitrogen).
Then, the products were treated with DpnI endonuclease to digest
parental DNA template and subsequently introduced into DH5α
cells. Plasmid extraction was performed and mutations conﬁrmed
by automated sequencing (Macrogen, Seoul, Korea). To generate a
deleted version of the 556 bp fragment containing only the N-box/
Class B sites a fragment of 354 bp was ampliﬁed by PCR using the fol-
lowing forward and reverse primers: F-5′- GTATGGTACC
TGCCCTCACTGGATT-3′and R-5′ GACTAAGCTTGATCACCGCAAACGCT-
3′. The restriction enzyme recognition sites KpnI and HindIII were
introduced in the F and R primers, respectively. PCR products were
cloned into the pGL3-basic (Promega, Madison, USA). The correct se-
quence and direction was conﬁrmed by sequencing (Macrogen,
Seoul, Korea). The generated plasmids were designated pGL3-hIDE-
556; pGL3-hIDE-Mut1; pGL3-hIDE-Mut2; pGL3-hIDE-Mut3 and
pGL3-hIDE-354.
N2aSW cells (4×104) were plated in a 24-well plate 16 h prior to
co-transfection using Lipofectamine LTX (Invitrogen, Carlsbad, USA)
with 200 ng of the indicated reporter constructs or equimolar amount
of empty vector pGL3-Basic and HA-NICD or HA-Hey-1 or FLAG-HES-
1 cDNAs, respectively. To control transfection efﬁciency pRL-TK-
Renilla Luciferase plasmid (Promega, UK) was also included in trans-
fections. Forty-eight hours later, cells were lysed using Dual-
Luciferase Reporter Assay System (Promega, Madison, USA) and lu-
minescence measured in a Tecan Genius (Männedorf, Switzerland).
Values for each experimental condition were calculated as a ratio of
luminescence obtained for ﬁreﬂy/renilla. Results are mean values of
4 independent transfected wells performed by duplicate and are
expressed as percentage relative to control (100%).
2.10. Quantiﬁcation of extracellular Aβ levels
Conditioned media were collected 24 h after transfection, spun at
1000×g for 5 min to pellet cell debris and diluted 1:100. Aβ40 levels
were quantiﬁed by using a commercial ELISA kit (Covance, Princeton,
USA). Data for each set duplicate transfection was averaged, the con-
trol in each set normalized to 100% and data presented as percentage
of control.
2.11. IDE and BACE-1 enzymatic activity assay
IDE was immunoprecipitated from conditioned supernatant or
hippocampal cytosolic fractions with anti-IDE monoclonal antibodies
as described [27] and proteolytic activity was performed by using
125
I-
insulin as substrate as previously reported [21]. Activity assays for
BACE-1 were performed by using synthetic peptide substrate (MCA-
Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-Lys-(DNP)-Arg-Arg-NH2)
from R&D Systems (Minneapolis, USA) and crude extracts following
procedures previously described [11].
2.12. Animals and surgical procedures
A total of 6 mice, ages ranging from 8 to 12 months weighing be-
tween 25 and 30 g, were maintained under controlled temperature
and light with water and food ad libitum. All animal procedures
were performed according to the rules, standards and the regulations
of the National Institute of Health, USA. Animal experiments were ap-
proved by the Institutional Commission for the Care and Use of the
230 M.C. Leal et al. / Biochimica et Biophysica Acta 1823 (2012) 227–235Laboratory Animals of Fundación Instituto Leloir. The stereotaxic co-
ordinates for injection into the hippocampus were antero posterior
2.1 mm from bregma; lateral 1.3 mm; ventral: 1.3 mm. For injections,
mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg
xylazine intraperitoneally. The skull was immobilized in a stereotaxic
apparatus (Stoelting, Illinois, USA). A hole was drilled in the cranium
by circular movements with a hand-held drill (Drimer). Mice were
injected with 2 μg of JAG-1 (in 1 μl PBS) or vehicle (PBS), using a
50 μm ﬁnely stretched glass capillary (Dumont). Animals were sacri-
ﬁced 3 days post injection.
2.13. Statistical analysis
All experiments were performed in triplicate and values presented
as means±SEM. Data were analyzed by Student's t test, one-way or
two-way ANOVA followed by post-hoc Bonferroni tests for compari-
son among means using GraphPad Prism 3.0 software. Statistical sig-
niﬁcance was set at pb0.05.
3. Results
3.1. Notch activation is increased in hippocampal formation of SAD
patients
To assess Notch activation in SAD brains, nuclei from frozen hip-
pocampal samples of SAD and non demented control (NDC) were iso-
lated. In nuclear fractions we detected an increase of ~40% in NICDA
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Fig. 1. Notch pathway activation, IDE and BACE-1 transcript levels and activity in SAD
brains. (A) Upper panel, representative Western blot of the expression of NICD protein
in nuclear extracts of SAD and control (NDC) hippocampal samples normalized by pro-
tein content. Arrow indicates NICD fragment. Lower panel, Coomassie blue staining of
the PVDF membrane corresponding to the Western blot described above. (B); (C) and
(D) Hey-1, IDE and BACE-1 mRNA levels in SAD hippocampus (n=5). Each point rep-
resents the mean value of at least 3 independent experiments performed by triplicate
for each sample. The mean±SEM in SAD relative to NDC cases are indicated. (E) Per-
centage of
125
I-insulin degraded by endogenous IDE in NDC and SAD samples as deter-
mined by TCA precipitation. (F) BACE-1 activity in NDC and SAD hippocampal extracts.
Bars represent the mean±SEM. of four independent experiments performed in tripli-
cate; *pb0.05 compared with NDC. Note that Notch activation, IDE and BACE-1 activi-
ties were obtained from the same hippocampal region.immunoreactivity in SAD as compared to NDC (Fig. 1A, left upper
panel). In addition, we isolated total RNA from each hippocampal
sample and by QRT-PCR we found an ~2.5-fold increase (2.43±
0.63) in the mRNA of Hey-1, a downstream Notch target gene
(Fig. 1A, right panel). In an effort to correlate Notch activation with
the gene transcription of relevant enzymes involved in the regulation
of Aβ metabolism in SAD brain, we examined IDE and BACE-1 mRNA
levels. In accordance with previous reports [11,16] we detected an
~1.5-fold decrease (−0.340±0.54) and an ~2.5-fold increase (2.36±
0.44) in IDE (Fig. 1B, left panel) and BACE-1 (Fig. 1C, left panel) tran-
script levels, respectively, in SAD as compared to NDC. In addition,
human hippocampal homogenates with increased Notch activation
were analyzed for IDE and BACE-1 activities. Concurrentwith published
ﬁndings [28], by combining
125
I-insulin degradation and trichloroacetic
acid (TCA) precipitation, a signiﬁcant reduction of IDE proteolytic activ-
ity (~26%) was found in SAD compared to NDC (Fig. 1B, right panel).
BACE-1 activity, as assessed with a ﬂuorogenic peptide substrate, was
increased (~20%) in the hippocampal homogenates of SAD as compared
to NDC, in agreement with previous reports [11] (Fig. 1C, right panel).
3.2. Notch signaling pathway activation impacts on Aβ metabolism
As a ﬁrst attempt to analyze the effect of Notch signaling activation
on Aβ metabolism, a mouse neuroblastoma cell line expressing APP
with the Swedish mutation (N2aSW) was transiently transfected with
NICD or a constitutively activated form of Notch that is a substrate of
γ-secretase, ΔE-Notch. As expected, a 4-fold increase (3.75±0.50;
n=7) in Hey-1 mRNA levels were observed in NICD as compared
to mock-transfected cells. Transfection with ΔE-Notch resulted in a 2-
fold-increase (2.23±0.40; n=3) of Hey-1 transcripts as compared to
controls and this effect was partially reverted (1.27±0.16) by the addi-
tion of L-685,458, a selective γ-secretase inhibitor known to inhibit
Notch signaling in vitro (Fig. 2A). Importantly, in N2aSW cells over-
expressing Hey-1 or NICD extracellular steady-state Aβ levels were in-
creased ~48% (148±15.4; n=4; pb0.05) and ~68% (167.5±21.7;
n=4; pb0.05), respectively, as compared to mock-transfected cells
(100%) (Fig. 2B) suggesting a direct impact of Notch signaling on Aβ
production and/or degradation.
3.3. Notch signaling pathway activation impacts on endogenous IDE and
BACE-1 mRNA levels
To test if Notch signaling activation may modulate mRNA levels of
proteases involved on Aβ metabolism N2aSW cells were transfected
with NICD cDNA and mRNA levels of IDE and BACE-1 determined by
QRT-PCR. As expected, a 4-fold-increase (4.18±0.45) in Hey-1
mRNA was observed (not shown). Interestingly, a decrease of ~1.5
fold (−1.260±0.07, n=4) on endogenous IDE mRNA levels was
conﬁrmed and a 3-fold increase (2.5±0.8; n=3) of endogenous
BACE-1 transcripts was detected (Fig. 2C).
3.4. Notch signaling pathway activation impacts on IDE and BACE-1 pro-
teolytic activity
To determine if reduction of IDE and increments of BACE-1 mRNA
levels were reﬂected in IDE and BACE-1 enzymatic activity, IDE was
immunoprecipitated from conditioned media of mock- or NICD-
transfected N2aSW cells (Fig. 3A, left panel) and a signiﬁcant reduc-
tion in extracellular IDE protein content was detected (Fig. 3A, right
panel) (0.18 vs. 0.12; pb0.05) in accordance with a signiﬁcant reduc-
tion of IDE proteolytic activity (48.5%±5.17; pb0.05), as compared to
mock-transfected cells (Fig. 3B, left panel). Moreover, a signiﬁcant in-
crease in the percentage of BACE-1 proteolytic activity was observed
in ΔE-Notch as compared to mock-transfected N2aSW cells
(154%±0.12) which was reverted by L-685,458 treatment
(0.74%±0.60) (Fig. 3B, right panel).
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Fig. 2. Effect of Notch signaling pathway activation on extracellular Aβ and on IDE and
BACE-1 transcripts levels. (A). Expression of Hey-1 mRNA in N2aSW cells transfected
with NICD, or ΔE-Notch-construct in the presence and absence of γ-secretase inhibitor
L-685,458. Bars indicate the mean value±SEM of at least 3 independent experiments
performed in triplicate in NICD or ΔE-Notch-construct relative to mock-transfected
cells. (B) Analysis of Aβ40 in the supernatants of cells transfected with empty vector
(mock), NICD, or Hey-1 cDNAs, respectively. Bars indicate the mean value±SEM;
*pb0.05 compared with mock-transfected cells; n.s., not signiﬁcant differences in ex-
tracellular Aβ levels between NICD and Hey-1 N2aSW transfected cells. (C) IDE and
BACE-1 mRNA levels in cells transfected with NICD construct. Bars indicate the mean
value±SEM of at least 3 independent experiments performed in triplicate in NICD construct
relative to mock-transfected cells.
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Fig. 3. Effect of Notch signaling pathway activation on the proteolytic activity of IDE
and BACE-1 (A) Left upper panel, Western blot with BC2 of 1C1/3A2 ipp from superna-
tants of mock-and NICD- N2aSW transfected cells. Left lower panel, Coomassie blue
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Taking into account that in the −582/−26 promoter region we
detected by in silico analysis putative Notch target genes binding
sites (schematically depicted in Fig. 4A) and knowing that the canon-
ical Notch signaling is mediated by HES and/or Hey, which are de-
scribed as transcriptional repressors, we explored whether Notch
activation down regulates IDE promoter activity. As a proof of concept
we decided to co-transfect N2aSW cells with the IDE 5′region
(556 bp) fused to Luciferase (LUC) and NICD or Hey-1, or HES-1, or
empty vector, respectively. There was a signiﬁcant reduction on IDE
promoter activity in NICD (61.99%±4.38; pb0.01), Hey-1
(66.61%±7.37; pb0.01) and HES-1 (7.65±0.81; pb0.01) as com-
pared to mock-transfected cells (100%) (Fig. 4B) suggesting the pres-
ence of functional sites that negatively regulate IDE transcription.
When the putative E-box, Class C1 and the overlapping N-box/
Class B consensus binding sites on the wild type 556 promoter (WT-
556) were mutated (Mut-1, Mut-2 and Mut-3, respectively) the tran-
scriptional activity increased in Mut-2 and Mut-3 but not in Mut-1
(Fig. 4 C) suggesting that site 1 lacks an inhibitory effect while sites
2 and 3 function as repressors of IDE transcriptional activity. Consis-
tently, after NICD transfection the negative regulation on the WT-
556 promoter was reverted in the Mut-3 but not in the Mut-2 con-
struct (Fig. 4D) indicating that site 3 is a relevant functional site and
indeed it may be partially responsible for the Notch-mediated inhibi-
tion of the IDE gene expression probably by the direct impact of HES-1
andHey-1 on the−310/–305 and−308/–303 binding sites. However,
disruption of site 2 (in the presence of a functional site 3) is not
enough to revert the repression of IDE transcription. In addition,
when co-transfection of Hey-1 and Mut-3 construct was done, the in-
hibition was not reverted (not shown) suggesting the relevance of a
functional Hey-1 binding site located at −379/−372 (referred as
Class C1) in accordance with data of binding capacity presented in
Table 1. Furthermore we prepared a deleted version (356 bp) contain-
ing the overlapping N-box/Class B site (Fig. 4E upper panel). Our re-
sults showed that the transcriptional activity of the pGL3-hIDE-356
promoter is increased as compared to pGL3-hIDE-556 promoter in ac-
cordance with the presence of an inhibitory site (Class C1) located at
upstream (−379/−372 bp) in the long construct. Moreover, we
detected a signiﬁcant reduction on pGL3-hIDE-356 promoter activity
after NICD, Hey-1 and HES-1 transfection reinforcing the functionality
of this site on the inhibition of IDE transcription.
3.6. Ligand-induced activation of Notch modiﬁes IDE expression levels in
vitro and in vivo
N2aSW cells were exposed to JAG-1 synthetic peptide, homologous
to the δ/Serrate/Lag-2 domain of Jagged1 known to activate Notch path-
way [29]. After JAG-1 exposure an increase of ~20% (1.21±0.04) in
Hey-1 mRNA was detected (Fig. 5A) in accordance with previous re-
ports [30], and ~2-fold reduction (−2.00±0.41; n=4) of IDE tran-
scripts was observed (Fig. 5B). As a preliminary approach to
determine the in vivo role of Notch signaling on IDE transcription we
aimed to recapitulate an acute Notch pathway activation by performing
a single injection of JAG-1peptide into thehippocampus of Tg2576mice
(9.2±0.94 month). In this well-established AD mouse model the in-
crease in IDE protein observedwith aging occurred without any change
in mRNA levels [31–32] providing a rational model to evaluate acute
Notch-mediated IDE mRNA modulation. To assess the basal activation
status of the Notch pathway in Tg2576 mice, Hey-1 mRNA levels were
measured by QRT-PCR. No statistically signiﬁcant differences were
detected in Hey-1 transcript levels between non transgenic (NTg) and
Tg2576 mice (Fig. 6A) suggesting that Notch activation is not a conse-
quence of Aβ accumulation in this mouse model (32). After 3 days of
JAG-1 injection, QRT-PCR showed an increase of ~30% on Hey-1 and
HES-1 mRNA levels (Fig. 6B). In contrast, IDE mRNA abundance was
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compared to control (Fig. 6C) suggesting a direct impact of Notch sig-
naling on IDE transcription in vivo.
4. Discussion
A range of different studies has produced conﬂicting results for
IDE expression in SAD brains [16,18–19,21,28,33]. In this study, we
measured mRNA and enzyme activity for IDE in hippocampus of a se-
ries of well-characterized patients and control cases and correlated
these ﬁndings to Notch signaling activation. We found lower IDE
mRNA and proteolytic activity in SAD compared with NDC consistent
with ﬁndings from the original reports [16,28] and reinforcing the
role of IDE as a dominant Aβ protease in regulating the steady-state
levels of Aβ in SAD. Moreover, our data provide direct evidence that
Notch pathway is activated in the hippocampi of SAD cases as com-
pared to NDC and that such activation may be implicated in the
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lism. This hypothesis was supported experimentally in vitro by trans-
fection of neuroblastoma cells and in vivo by intracranial injections in
mice of a Notch ligand.
We showed that in N2aSW cells, over-expression of NICD or Hey-1
resulted in higher steady-state levels of extracellular Aβ. These results
were consistent with reduced levels of IDE and increased levels of
BACE-1 endogenous mRNA and enzymatic activities, respectively.
In our report we show that IDE is a new and direct target of HES-1
and Hey-1, key downstream targets of Notch signaling. So far, and de-
spite its recognized importance in insulin and Aβ clearance, little is
known about how IDE gene expression is regulated. The data
reported to date are limited to the description of IDE promoter as a
CG-rich, “slippery” and typical of housekeeping genes with several
transcription initiation sites [20].
It was recently reported that the regulation of IDE gene expression
may be mediated by peroxisome proliferator-activated receptor γ
(PPARγ) which promotes gene transcription through binding to func-
tional elements located at −1549/–1530 bp in IDE 5′ DNA region
[34]. In addition, it was shown that selective PPARδ agonist
(GW742) [35] and noradrenaline precursor L-threo-3,4-dihydroxy-
phenylserine (L-DOPS) [36] increase mRNA levels of IDE in 5xFAD
mice. Moreover, in vitro analyses in primary cultures of rat hippocam-
pal neurons revealed that 17 beta-estradiol (17beta-E2) increased
IDE in both mRNA and protein levels upon activation of estrogen re-
ceptor (ER) β and phosphatidylinositol 3-kinase (PI3-K) signaling
cascade [37] By contrast, in primary cultures of astrocytes it was
shown that glucocoticorticoids (GC) decrease IDE expression through
the activation of GC receptors [38].
In our study, we have obtained data suggesting that HES-1 and
Hey-1 directly repress IDE transcription in N2aSW cells through bind-
ing to the proximal IDE promoter. Our data show that endogenous
and exogenous HES-1 and Hey-1 can be recruited to the IDE promoter
in N2aSW cells presumably through an E-box suggesting that this
proximal consensus binding site in the IDE promoter region is a rele-
vant element in IDE transcription after Notch activation.
Our in vivo experiments strongly support that, by the age at which
substantial Aβ is present in Tg2576 mice, Notch signaling is not al-
tered as compared to non-Tg. This indicates that Notch may not be in-
volved in the amyloidogenic pathway in this animal model and
supports that Notch activation, as found in SAD is unlikely to be a sec-
ondary process due to Aβ accumulation. However, a transient and
acute Notch activation in Tg2576 mice impacts on IDE transcription.
These ﬁndings support that, at least in this animal model, changes
in Notch expression do not replicate what is found in human brain.
The time-course analysis of Notch pathway components and IDE ex-
pression as well as Aβ levels and memory deﬁcit in young Tg2576
mice will be a valuable experimental tool to test the hypothesis that
chronic Notch1 activation may accelerate Aβ-associated pathology.
The down-regulation of IDE mediated by Notch1 activation in SAD
brain may be a late-stage consequence of the pathological process.Alternatively, Notch activation in vulnerable regions such as the hip-
pocampus may be an early event in the disease that promotes the ac-
cumulation of Aβ. Although Jagged-1 is overexpressed in fetal DS
brain [39], the analysis of Notch pathway components and IDE ex-
pression in DS brains at different ages may help to clarify this issue.
The function of Notch in aging human brain has not been fully estab-
lished, yet, it seems likely that Notch signaling is involved in mamma-
lian adult neurogenesis at the subventricular zone (SVZ) and
subgranular layer of the hippocampus. More speciﬁcally, the role of
Notch has been related to the maintenance of the pool of neuronal
precursor cells (NPCs) in these neurogenic regions (reviewed in
[40]). In addition, it was also speculated that expression of Notch1
protein in post-mitotic neurons from adult brain in areas with high
synaptic activity/plasticity, such as hippocampus and cerebellum
may play a role in neuronal plasticity, maintenance of complex
neurite arborization or synaptic remodeling during memory forma-
tion [5]. A very recent report showed that expression of several
FAD PS1 mutants in NPCs leads to impaired NPC self-renewal due a
reduced γ-secretase cleavage of Notch [41]. If this defect in Notch
activation due to FAD PS mutations is widespread in the brain, it is
likely that increased amyloidogenesis in FAD is related primarily
to the processing of APP. Gene expression and immunohistochemical
studies show that Notch is over-expressed in neurogenic and non-
neurogenic regions in SAD [4,42] and adult DS brains [3,39]. Toge-
ther with our results, this evidence suggests that amyloidoge-
nesis in SAD may be favored by a Notch-mediated decrease of IDE
expression.
Several reports indicate that Notch signaling is increased in re-
sponse to ischemic, traumatic or cryo-injury in the adult brain result-
ing in cell proliferation, variable effects upon neurogenesis, microglia
activation and inﬂammation [43–46]. The inhibition of endogenous
Notch signaling during these pathologic processes may help to evalu-
ate the actual functional signiﬁcance of activated Notch in neurode-
generative diseases.
Taken together, we propose that binding of HES-1 and Hey-1 to
the functional N-box of the IDE gene promoter may cooperate with
a number of factors including other bHLH factors or other transcrip-
tional regulators, already not described, and that the combined out-
put of these interactions determines the decrement of IDE gene
transcription in SAD brain. Moreover, taking into account that IDE is
capable of degrading AICD [47–48], and that AICD positively regulates
BACE-1 expression, Notch-mediated down-regulation of IDE would
result in increased BACE1 levels, further enhancing the production
of Aβ, as schematically represented in Fig. 7. Due to the multiplicity
of gene targets and cellular processes regulated by Notch, it is difﬁcult
to speculate about how its activation in SADmay impact upon the dis-
ease course. Similarly, several cell-speciﬁc pathways regulate the con-
trol of IDE expression. The identiﬁcation that their activities can be
modulated by Notch signaling may provide novel insights on the con-
sequences of therapeutic strategies for AD based on γ-secretase phar-
macological inhibition.
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The following are the main conclusions of this work:
1- The decrement of IDE transcript levels observed in the hippocam-
pus of SAD brains as compared to controls may be explained by
the increment of Hey-1, a Notch target gene and a family member
of transcriptional repressors.
2- Extracellular Aβ accumulation may be the consequence of local
Notch activation and reduction of IDE mRNA and enzymatic activ-
ity levels.
3- The inhibitory effect of Notch activation on IDE transcription is
mediated by the direct binding of HES-1 and Hey-1 to both func-
tional sites located at −379/–372 and −310/–303 in the IDE
proximal promoter.
4- Intracranial injection of the Notch ligand JAG-1 in Tg2576 mice in-
duced overexpression of HES-1 and Hey-1 and reduction of IDE
mRNA levels, respectively.
5- Our results support that a Notch-dependent IDE transcriptional mod-
ulation may impact on Aβ metabolism providing a functional link
between Notch signaling and the amyloidogenic pathway in SAD.
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